LYON, France, July 12 – An Aventis executive said Thursday it was too early to speculate about how the proposed sale of Aventis CropScience to Bayer would impact the company’s genomics efforts.

“I don’t know if there will be any effect; it’s too early to tell,” Georges Freyssinet, head of global genomic research at CropScience, told GenomeWeb.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.